Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients
- PMID: 30186987
- PMCID: PMC6101156
- DOI: 10.18502/cmm.4.1.27
Prevalence of vulvovaginal candidiasis in gynecological practices in Germany: A retrospective study of 954,186 patients
Abstract
Background and purpose: To the best of our knowledge, no information is available regarding the treatment of vulvovaginal candidiasis in gynecological practices. The goal of this study was to analyze the prevalence of vulvovaginal candidiasis (VVC) and the drugs prescribed for the treatment of this condition in women followed in gynecological practices in Germany.
Materials and methods: All the women followed in 262 gynecological practices between November 2014 and October 2016 were included in this study. The first outcome was the prevalence of patients diagnosed with VVC during this period. The second outcome was the prevalence of women with VVC who received an appropriate vaginal or systemic antimycotic prescription within 30 days after their first VVC diagnosis. Covariables included the use of gynecological/systemic antibiotics, consumption of oral/vaginal contraceptives, cancer, pregnancy, diabetes, and psychiatric diseases including depression, anxiety, and adjustment and somatoform disorders.
Results: Between 2014 and 2016, 954,186 women were followed in gynecological practices, and 50,279 (5.3%) women were diagnosed with VVC during the same period. The use of gynecological antibiotics (OR=2.88), systemic antibiotics (OR=1.45), oral contraceptives (OR=1.74), and vaginal contraceptives (OR=1.84) were associated with an increase in the risk of VVC diagnosis. Cancer (OR=1.20) and pregnancy (OR=1.59) were additional risk factors. Approximately 75% of women diagnosed with VVC received an antimycotic prescription. The three most frequently prescribed drugs were clotrimazole (72%), fluconazole (14%), and nystatin (6%).
Conclusion: More than 5% of women were diagnosed with VVC and the majority of them received an appropriate prescription.
Keywords: Germany; Gynecological practices; Prescription; Prevalence; Vulvovaginal candidiasis.
Conflict of interest statement
All authors declare that they have no conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures




Similar articles
-
VULVOVAGINAL CANDIDIASIS AFTER GYNECOLOGICAL SURGERIES AND ADVERSE PREGNANCY OUTCOME IN UKRAINE: A MULTICENTRE STUDY.Wiad Lek. 2023;76(12):2556-2563. doi: 10.36740/WLek202312102. Wiad Lek. 2023. PMID: 38290017
-
Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.BMC Pregnancy Childbirth. 2020 May 6;20(1):266. doi: 10.1186/s12884-020-02963-3. BMC Pregnancy Childbirth. 2020. PMID: 32375724 Free PMC article.
-
[INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].Akush Ginekol (Sofiia). 2016;55(4):20-29. Akush Ginekol (Sofiia). 2016. PMID: 29370489 Bulgarian.
-
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors.Crit Rev Microbiol. 2016 Nov;42(6):905-27. doi: 10.3109/1040841X.2015.1091805. Epub 2015 Dec 21. Crit Rev Microbiol. 2016. PMID: 26690853 Review.
-
The Relationship Between Vulvovaginal Candidiasis and Provoked Vulvodynia: A Systematic Review.J Sex Med. 2018 Sep;15(9):1310-1321. doi: 10.1016/j.jsxm.2018.07.011. Epub 2018 Aug 23. J Sex Med. 2018. PMID: 30145093
Cited by
-
Accuracy of the BD MAX™ vaginal panel in the diagnosis of infectious vaginitis.Eur J Clin Microbiol Infect Dis. 2019 May;38(5):877-882. doi: 10.1007/s10096-019-03480-8. Epub 2019 Jan 26. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30685805
-
Molecular epidemiology of Candida tropicalis isolated from urogenital tract infections.Microbiologyopen. 2020 Nov;9(11):e1121. doi: 10.1002/mbo3.1121. Epub 2020 Sep 27. Microbiologyopen. 2020. PMID: 32985133 Free PMC article.
-
The right bug in the right place: opportunities for bacterial vaginosis treatment.NPJ Biofilms Microbiomes. 2022 May 2;8(1):34. doi: 10.1038/s41522-022-00295-y. NPJ Biofilms Microbiomes. 2022. PMID: 35501321 Free PMC article. Review.
-
Urogenital Infections Among Women Attending Mwingi Hospital, Kitui County, Kenya: Safeguarding Antibiotics Through Microbiological Diagnosis.East Afr Health Res J. 2024;8(1):99-105. doi: 10.24248/eahrj.v8i1.754. Epub 2024 Mar 28. East Afr Health Res J. 2024. PMID: 39234350 Free PMC article.
-
Functional Synergy Of Antimicrobial Peptides And Chlorhexidine Acetate Against Gram-Negative/Gram-Positive Bacteria And A Fungus In Vitro And In Vivo.Infect Drug Resist. 2019 Oct 15;12:3227-3239. doi: 10.2147/IDR.S218778. eCollection 2019. Infect Drug Resist. 2019. PMID: 31686873 Free PMC article.
References
-
- Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 2003;110(1):66–72. - PubMed
-
- Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis. 2013;17(3):340–5. - PubMed
-
- Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7(2):182–7. - PubMed
-
- Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998;92(5):757–65. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources